## Contents

| Fore    | word  | ix  |
|---------|---|-----|
| Preface |   |     |
| Intro   | duction   | xii |
|         | The slobel concer burden  | 45  |
| 1       | The global cancer burden  | 15  |
| 1.1     | The burden and prevention of premature deaths from noncommunicable diseases, including cancer: a global perspective | 16  |
| 1.2     | Global trends in cancer incidence<br>and mortality  | 23  |
| 1.3     | Transitions in human development and the global cancer burden   | 34  |
| Knov    | wn causes of human cancer by organ site   | 45  |
| 2       | Causes of cancer, including hazardous circumstances   | 49  |
| 2.1     | Tobacco products<br>Massive and still growing causes of cancer<br>worldwide   | 50  |
| 2.2     | Infectious agents<br>Missed opportunities for prevention  | 61  |
| 2.3     | Alcohol consumption<br>A leading risk factor for cancer   | 68  |
| 2.4     | Sunlight and ultraviolet radiation<br>Affecting skin cancer incidence in many countries                             | 77  |
| 2.5     | lonizing radiation and radiofrequency<br>electromagnetic fields<br>Further clarification of particular risks        | 84  |
| 2.6     | Diet and nutrition<br>Understanding which factors are critical  | 92  |
| 2.7     | Physical activity, sedentary behaviour,<br>and obesity<br>Established and emerging modifiable risk factors          | 101 |
| 2.8     | Dietary carcinogens<br>A continuing concern in various contexts   | 109 |
| 2.9     | Contamination of air, water, soil, and food<br>The challenge is to characterize specific risks                      | 115 |
| 2.10    | Occupation<br>The need for continuing vigilance   | 127 |
| 2.11    | Pharmaceutical drugs<br>A current focus on hormones   | 137 |
|         | d Cancer Research Fund International/<br>rican Institute for Cancer Research  | 144 |

| 3    | Biological processes in cancer development   | 147 |
|------|--|-----|
| 3.1  | Sporadic cancer<br>Tumorigenesis in the absence of an established<br>or avoidable cause                      | 148 |
| 3.2  | Genomics<br>Susceptibility and somatic patterns  | 154 |
| 3.3  | Gene–environment interactions<br>The preventive implications are still not clear                             | 164 |
| 3.4  | DNA repair and genetic instability<br>Endogenous and exogenous sources of damage<br>and hereditary syndromes | 170 |
| 3.5  | Inflammation<br>Playing a pivotal role in cancer pathogenesis  | 181 |
| 3.6  | Reproductive and hormonal factors<br>Important contributors to several cancer sites                          | 189 |
| 3.7  | Metabolic change and metabolomics<br>Emerging approaches and new insights                                    | 200 |
| 3.8  | Epigenetics<br>Potential in diagnostics, therapy, and prevention   | 206 |
| 3.9  | Immune function<br>From the tumour microenvironment to therapeutic<br>targeting                              | 215 |
| 3.10 | The microbiome<br>Its influence on tumorigenesis and therapy   | 221 |
| 3.11 | Identifying carcinogens from 10 key<br>characteristics<br>A new approach based on mechanisms                 | 229 |
| The  | IARC Handbooks of Cancer Prevention  | 236 |
| 4    | Inequalities that affect cancer prevention   | 237 |
| 4.1  | Inequalities between and within countries<br>Impact on cancer prevention                                     | 238 |
| 4.2  | Socioeconomic factors and cancer<br>prevention in Africa<br><i>Cervical cancer as an example</i>             | 246 |
| 4.3  | Cancer in urban and rural communities<br>in China<br>Patterns reflect social dynamics                        | 252 |
| 4.4  | Socioeconomic factors and cancer<br>prevention in India<br>Diverse interventions are needed                  | 258 |

| 4.5      | Variations in implementation of cancer<br>screening in European countries<br><i>Striving for best practice</i> | 266 |
|----------|--|-----|
| 4.6      | in the USA   | 276 |
| 4 7      | A long-standing, persistent cause of inequity  | 200 |
| 4.7      | Cancer in Indigenous populations<br>Focusing on inequalities that are sometimes<br>invisible                   | 288 |
| Towa     | ards the World Code Against Cancer   | 295 |
| 5        | Preventing particular tumour types   | 297 |
| <u> </u> | ide to the epidemiology data in Section 5:   | 298 |
|          | enting particular tumour types   | 200 |
| 5.1      | Lung cancer<br>Continues to be the leading cause of cancer death   | 299 |
| 5.2      | Head and neck cancers  | 310 |
|          | New etiological insights   |     |
| 5.3      | 1 0  | 323 |
|          | A tale of two malignancies   |     |
| 5.4      | Stomach cancer   | 333 |
| 5.5      | Still one of the main cancer types worldwide<br>Colorectal cancer  | 344 |
| 5.5      | Decreasing disparities and promoting prevention<br>are policy priorities                                       | 344 |
| 5.6      | Liver cancer   | 355 |
|          | An infectious disease for many communities   |     |
| 5.7      | Pancreatic cancer<br>Many risk factors too poorly characterized<br>to enable prevention                        | 367 |
| 5.8      | Skin cancer  | 374 |
|          | A focus on primary prevention  |     |
| 5.9      | Breast cancer  | 382 |
| 5 40     | Multiple, often complex, risk factors  |     |
| 5.10     | Cervical cancer<br>Successes in some communities to be extended<br>worldwide                                   | 394 |
| 5.11     | Endometrial cancer<br>Prevention through control of obesity  | 403 |
| 5.12     | Ovarian cancer<br>Complicated etiology and very few preventive   | 411 |
| E 10     | options  | 421 |
| 5.15     | Prostate cancer<br>Challenges for prevention, detection, and<br>treatment                                      | 421 |
| 5.14     | Testicular cancer<br>New inroads into early diagnosis  | 430 |
| 5 15     | Bladder cancer   | 439 |
| 0.10     | A genotoxic causal agent recognized  | 100 |
|          |  |     |

| 5.16  | Kidney cancer<br>Multiple risk factors, but currently limited<br>preventive strategies  | 447 |
|---|---|-----|
| 5.17  | Brain cancer<br>Increasing attention on the immune response   | 454 |
| 5.18  | Thyroid cancer<br>The challenge of overdiagnosis  | 461 |
| 5.19  | Non-Hodgkin lymphoma<br>Complex etiology, including the role of immune<br>function  | 468 |
| 5.20  | Leukaemias<br>Understanding pathogenesis through similarities<br>and differences  | 477 |
| WHO Report on Cancer: Setting priorities, 4 investing wisely and providing care for all |   |     |
| 6   | The basis for, and outcomes<br>from, prevention strategies  | 487 |
| Toba  | acco cessation: the WHO perspective   | 488 |
| 6.1   | Changing behaviour<br>The need for sustainable implementation   | 499 |
| 6.2   | Improving diet and nutrition, physical<br>activity, and body weight<br><i>From evidence to practice</i>                                       | 506 |
| 6.3   | Vaccination<br>The prospect of eliminating some cancer types  | 513 |
| 6.4   | Preventive therapy<br>Certain interventions clearly established   | 522 |
| 6.5   | Managing people with high and moderate<br>genetic risk<br><i>Genomic tools to promote effective cancer risk</i><br><i>reduction</i>           | 530 |
| 6.6   |   | 540 |
|   | From biology to public health   |     |
| 6.7   | Circulating DNA and other biomarkers for<br>early diagnosis<br><i>Great potential, but challenges recognized</i>                              | 550 |
| 6.8   | Governmental action to control carcinogen<br>exposure<br><i>Multiple options covering diverse scenarios</i>                                   | 557 |
| 6.9   | Prevention strategies common to<br>noncommunicable diseases<br><i>A focus on tobacco, alcohol, obesity, and physical</i><br><i>inactivity</i> | 565 |
| Contributors  |   |     |
| Disclosures of interests  |   |     |
| Sources   |   |     |
| Subject index   |   | 595 |